Sarepta Therapeutics, Inc.
SRPTNext catalyst
Eteplirsen
Duchenne Muscular Dystrophy
Get an email about SRPT's next catalysts
Track Sarepta Therapeutics (SRPT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 3 more upcoming events in our data (earnings, Phase 2 readout, regulatory event).See the timeline
5 upcoming, 0 past
Eteplirsen Phase 3 Est. Readout (MIS51ON)
Primary completion for Eteplirsen trial (NCT03992430) in Muscular Dystrophy, Duchenne
SourceSRPT Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $0.17 | FQ end Sep/2026 | Call: amc
Data Readout
Sarepta reiterates its 2026 net product revenue guidance of $1.2B-$1.4B and targets Cohort 8 data delivery by year-end 2026.
Clinical data showing clinically meaningful benefit in older patients who are able to walk
SRP-1003 IV Infusion Phase 2 Est. Readout
Estimated primary completion for SRP-1003 IV Infusion trial (NCT06138743) in Myotonic Dystrophy 1. Topline data typically follows completion by weeks to months.
SourceRegulatory — exon skipping drugs
The FDA will decide on the future of Sarepta's exon skipping drugs by end of February 2027. Flare Therapeutics announced Anna Protopapas as new CEO.
SourceHow SRPT's past catalysts played out
Market Overview
Stock performance and key metrics
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs.
WebsiteSRP-9003
Limb-girdle Muscular Dystrophy
SRP-4045
Duchenne Muscular Dystrophy
Eteplirsen
Duchenne Muscular Dystrophy
Glucocorticoid
Limb-girdle Muscular Dystrophy
SRP-4053
Duchenne Muscular Dystrophy
Vyondys 53
Duchenne Muscular Dystrophy
RESTEN-MP
Coronary Artery Disease
Exondys 51
Duchenne Muscular Dystrophy
AVI-4658 (Eteplirsen)
Duchenne Muscular Dystrophy (DMD)
AVI-4658 for Injection
Duchenne Muscular Dystrophy
AVI-4658 (PMO)
Duchenne Muscular Dystrophy
Amondys 45
Duchenne Muscular Dystrophy
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SRP-9003 | Phase 3 | Limb-girdle Muscular Dystrophy | - | - |
SRP-4045 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
Eteplirsen | Phase 3 | Duchenne Muscular Dystrophy | - | Patent 2034 |
Glucocorticoid | Phase 3 | Limb-girdle Muscular Dystrophy | - | - |
SRP-4053 | Phase 3 | Duchenne Muscular Dystrophy | - | - |
Vyondys 53 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
RESTEN-MP | Phase 2 | Coronary Artery Disease | - | - |
Exondys 51 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
AVI-4658 (Eteplirsen) | Phase 2 | Duchenne Muscular Dystrophy (DMD) | - | - |
AVI-4658 for Injection | Phase 2 | Duchenne Muscular Dystrophy | - | - |
AVI-4658 (PMO) | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Amondys 45 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Duchenne Muscular Dystrophy
5 drugs in this indication
Limb-girdle Muscular Dystrophy
1 drug in this indication
Coronary Artery Disease
1 drug in this indication
Duchenne Muscular Dystrophy (DMD)
1 drug in this indication
non-ambulatory dystrophy
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Sarepta Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 12 drug candidates in Sarepta Therapeutics, Inc.'s (SRPT) pipeline across Phase 3, Phase 2. Its lead program is Eteplirsen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Sarepta Therapeutics, Inc.'s next FDA catalyst?→
Sarepta Therapeutics, Inc.'s (SRPT) next tracked catalyst is a Phase 3 readout expected October 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SRPT biotech catalysts?→
Add SRPT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Sarepta Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.